Search research articles
Contact Us
Filters
Showing results (91-100 of 174) with videos related to
Page
of 18
Sort By:
The Lancet. Oncology
|
August 6, 2019
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Michael Friedlander, Tarek Meniawy, Ben Markman, et al.
Gynecologic Oncology
|
December 4, 2010
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma
Andreas Obermair, Linda Mileshkin, Katharina Bolz, et al.
Journal of Cancer Survivorship : Research and Practice
|
March 31, 2021
Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy
Julia Lai-Kwon, Sarah Heynemann, Jacinthe Flore, et al.
Asia-Pacific Journal of Clinical Oncology
|
June 26, 2024
Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022
Nadia Hitchen, Adel Shahnam, Sathya Manoharan, et al.
Haematologica
|
July 21, 2007
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
Linda Mileshkin, Dirk Honemann, Peter Gambell, et al.
Translational Oncology
|
February 28, 2024
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
Bonnita Werner, Katrin M Sjoquist, David Espinoza, et al.
Internal Medicine Journal
|
December 6, 2018
The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia
Linda Mileshkin, Catherine Dunn, Hannah Cross, et al.
The Oncologist
|
November 21, 2020
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
Jeffrey S Ross, Ethan S Sokol, Holger Moch, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 3, 2021
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020
Andreas Obermair, Jim Nicklin, Val Gebski, et al.
British Journal of Cancer
|
October 21, 2016
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
, Prunella Blinman, Linda Mileshkin, et al.
Page
of 18
Search research articles
Search
Showing results (91-100 of 174) with videos related to
Sort By:
Page
of 18
The Lancet. Oncology
|
August 6, 2019
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Michael Friedlander, Tarek Meniawy, Ben Markman, et al.
Gynecologic Oncology
|
December 4, 2010
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma
Andreas Obermair, Linda Mileshkin, Katharina Bolz, et al.
Journal of Cancer Survivorship : Research and Practice
|
March 31, 2021
Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy
Julia Lai-Kwon, Sarah Heynemann, Jacinthe Flore, et al.
Asia-Pacific Journal of Clinical Oncology
|
June 26, 2024
Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022
Nadia Hitchen, Adel Shahnam, Sathya Manoharan, et al.
Haematologica
|
July 21, 2007
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
Linda Mileshkin, Dirk Honemann, Peter Gambell, et al.
Translational Oncology
|
February 28, 2024
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial
Bonnita Werner, Katrin M Sjoquist, David Espinoza, et al.
Internal Medicine Journal
|
December 6, 2018
The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia
Linda Mileshkin, Catherine Dunn, Hannah Cross, et al.
The Oncologist
|
November 21, 2020
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
Jeffrey S Ross, Ethan S Sokol, Holger Moch, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 3, 2021
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020
Andreas Obermair, Jim Nicklin, Val Gebski, et al.
British Journal of Cancer
|
October 21, 2016
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
, Prunella Blinman, Linda Mileshkin, et al.
Page
of 18